The sale of this asset is expected to be completed in 1Q25 and will be supported by a number of global investors, including sovereign wealth funds and institutional investors, in addition to IS Fund V ...

Kazia Therapeutics (KZIA) is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib ...

PAX Health, a leading behavioral healthcare company backed by HCAP Partners and Hamilton Lane, today announced its ...